Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

101. Is the medical use of cannabis a therapeutic option for children?

are offered, always providing that this treatment course is carefully evaluated in individuals and in ongoing, well-designed research studies to determine safety and efficacy. Key Words: Cannabinoids; Children; Epilepsy; Medical marijuana; Nabiximols; Smoking   (...) Is the medical use of cannabis a therapeutic option for children? Cannabis is a psychoactive compound with a long history of recreational and therapeutic use. Current considerations regarding cannabis use for medical purposes in children have been stimulated by recent case reports describing its beneficial effect with refractory epilepsy. Overall, there are insufficient data to support either the efficacy or safety of cannabis use for any indications in children, and an increasing body of data

2016 Canadian Paediatric Society

102. Talking Pot with Youth: A Cannabis Communication Guide for Youth Allies

; and • Lead you through the spectrum for using cannabis and support you in having judgment-free conversations about cannabis with youth. What This Guide Will Not Do It does not replace professional screening for, or treatment of, cannabis use disorder. WHAT IS CANNABIS? Cannabis, more commonly called marijuana, pot or weed, is a greenish or brownish material consisting of the dried flowers and leaves of the cannabis plant, Cannabis sativa. Hashish or cannabis resin is the dried brown or black resinous (...) Talking Pot with Youth: A Cannabis Communication Guide for Youth Allies A Cannabis Communication Guide for Youth Allies Co-designed with input from youth and youth allies Acknowledgements This guide is stronger because of the expertise of the youth and youth allies who were involved in its creation. Authors: Katie Fleming, MA, and Anna McKiernan, MA This project was supported by the Canadian Institutes of Health Research and benefited from the advice of Health Canada. CCSA would like

2016 Canadian Centre on Substance Abuse

103. Systematic review with meta analysis: Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications

marijuana-related questions and to learn about its potential risks and benefits. 2 This review examines the potential benefits along with associated adverse events (AEs) of cannabinoids, in different forms, for various … Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright (...) Systematic review with meta analysis: Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time

2016 Evidence-Based Medicine

104. High-potency cannabis increases the risk of psychosis

High-potency cannabis increases the risk of psychosis High-potency cannabis increases the risk of psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High-potency cannabis increases the risk of psychosis Article Text Causes and risk factors High-potency cannabis increases the risk of psychosis Emma Barkus Correspondence to University of Wollongong, Wollongong, New South Wales, Australia; ebarkus{at}uow.edu.au Statistics from

2016 Evidence-Based Mental Health

105. Clinical and toxicological findings of acute intoxication with synthetic cannabinoids and cathinones Full Text available with Trip Pro

Clinical and toxicological findings of acute intoxication with synthetic cannabinoids and cathinones Reporting of the analytical and clinical findings of synthetic cannabinoids and cathinones is essential in carrying out a complete clinical assessment of new psychoactive substances.From 2012 to 2014, we examined synthetic cathinone and cannabinoid poisoning in six patients aged 22-42 years old. Analyses of these compounds were carried out using liquid chromatography-tandem mass spectrometry.The (...) observed clinical symptoms were similar to those reported for intoxication with synthetic cathinones and cannabinoids. In cases of intoxication with synthetic cathinones, the psychiatric and neurological symptoms were long-lasting, and these compounds were detected in serum for 15-48 h after use. Although the clinical symptoms induced by the synthetic cannabinoids disappeared within several hours after use, the range of serum concentrations of these compounds was ≤5 ng/mL for 1-3 h after use. In one

2015 Acute medicine & surgery

106. Cannabinoids in the Treatment of Epilepsy. (Abstract)

Cannabinoids in the Treatment of Epilepsy. 26672645 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Cannabinoids in the Treatment of Epilepsy. 94-5 10.1056/NEJMc1512758 Friedman Daniel D Devinsky Orrin O eng Letter Comment 2015 12 16 United States N Engl J Med 0255562 0028-4793 0 Anticonvulsants 0 Cannabinoids 0 Medical Marijuana AIM IM N Engl J Med. 2015 Sep 10;373(11):1048-58 26352816 N Engl J Med. 2016 Jan 7;374(1):94 26672646 Animals (...) Anticonvulsants therapeutic use Cannabinoids therapeutic use Epilepsy drug therapy Humans Medical Marijuana therapeutic use 2015 12 18 6 0 2015 12 18 6 0 2016 1 9 6 0 ppublish 26672645 10.1056/NEJMc1512758 10.1056/NEJMc1512758#SA2

2015 NEJM

107. Cannabinoids in the Treatment of Epilepsy. Full Text available with Trip Pro

Cannabinoids in the Treatment of Epilepsy. 26672646 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Cannabinoids in the Treatment of Epilepsy. 94 10.1056/NEJMc1512758 Killestein Joep J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticonvulsants 0 Cannabinoids 0 Medical Marijuana AIM IM N Engl J Med. 2015 Sep 10;373(11):1048-58 26352816 N Engl J Med. 2016 Jan 7;374(1):94-5 26672645 Animals Anticonvulsants therapeutic use (...) Cannabinoids therapeutic use Epilepsy drug therapy Humans Medical Marijuana therapeutic use 2015 12 18 6 0 2015 12 18 6 0 2016 1 9 6 0 ppublish 26672646 10.1056/NEJMc1512758 10.1056/NEJMc1512758#SA1

2015 NEJM

108. Cannabinoids in the Treatment of Epilepsy. Full Text available with Trip Pro

):94-5 26672645 N Engl J Med. 2016 Jan 7;374(1):94 N Engl J Med. 2016 Jan 7;374(1):94 26672646 Animals Anticonvulsants chemistry therapeutic use Cannabidiol chemistry therapeutic use Cannabinoids adverse effects chemistry therapeutic use Cannabis chemistry Dronabinol chemistry therapeutic use Epilepsy drug therapy Humans Medical Marijuana adverse effects therapeutic use 2015 9 10 6 0 2015 9 10 6 0 2015 9 30 6 0 ppublish 26352816 10.1056/NEJMra1407304 (...) Cannabinoids in the Treatment of Epilepsy. 26352816 2015 09 29 2019 01 17 1533-4406 373 11 2015 Sep 10 The New England journal of medicine N. Engl. J. Med. Cannabinoids in the Treatment of Epilepsy. 1048-58 10.1056/NEJMra1407304 Friedman Daniel D Devinsky Orrin O eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Anticonvulsants 0 Cannabinoids 0 Medical Marijuana 19GBJ60SN5 Cannabidiol 7J8897W37S Dronabinol I198VBV98I cannabidivarin AIM IM N Engl J Med. 2016 Jan 7;374(1

2015 NEJM

109. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use (...) in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

2015 Health Technology Assessment (HTA) Database.

110. Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Full Text available with Trip Pro

Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Cannabis is frequently used among individuals with first episode psychosis and is associated with poor clinical outcomes. However, little is known about the effect of cannabis use on the response to antipsychotic medications and how use could affect outcomes. Using natural language processing on clinical data from a large electronic case register, we sought to investigate whether resistance (...) to antipsychotic treatment mediated poor clinical outcomes associated with cannabis use.Data were obtained from 2026 people with first episode psychosis in south London, UK. Cannabis use documented in free text clinical records was identified with natural language processing. Data for age, sex, ethnicity, marital status, psychotic disorder diagnosis, subsequent hospital admission, and number of unique antipsychotic medications prescribed were obtained using the Clinical Record Interactive Search instrument

2015 Lancet

111. The Implications of Marijuana Legalization in Colorado Full Text available with Trip Pro

of Colorado, Aurora2Rocky Mountain Poison and Drug Center, Denver, Colorado. eng 1K23GM110516-01 GM NIGMS NIH HHS United States R56 DA038366 DA NIDA NIH HHS United States 1R56DA038366-01 DA NIDA NIH HHS United States K23 GM110516 GM NIGMS NIH HHS United States UL1 TR001082 TR NCATS NIH HHS United States Journal Article Research Support, N.I.H., Extramural United States JAMA 7501160 0098-7484 0 Medical Marijuana AIM IM Burns etiology Cannabis poisoning Child Colorado Food Humans Legislation, Drug Marijuana (...) The Implications of Marijuana Legalization in Colorado 25486283 2015 02 19 2018 11 13 1538-3598 313 3 2015 Jan 20 JAMA JAMA The implications of marijuana legalization in Colorado. 241-2 10.1001/jama.2014.17057 Monte Andrew A AA Department of Emergency Medicine, University of Colorado, Aurora2Rocky Mountain Poison and Drug Center, Denver, Colorado. Zane Richard D RD Department of Emergency Medicine, University of Colorado, Aurora. Heard Kennon J KJ Department of Emergency Medicine, University

2015 JAMA

112. Randomised controlled trial: Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosi Full Text available with Trip Pro

) study: safety and efficacy data for 12 months follow up . Pryce G , Riddall DR , Selwood DL , et al . Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids . Footnotes Competing interests None declared. Provenance and peer review Commissioned; internally peer reviewed. Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink (...) Randomised controlled trial: Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosi Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal

2015 Evidence-Based Medicine

113. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia

Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Article Text Causes and risk factors Environmental

2015 Evidence-Based Mental Health

114. Intervening early in children with bipolar disorder: is there a pot at the end of the Rainbow? Full Text available with Trip Pro

Intervening early in children with bipolar disorder: is there a pot at the end of the Rainbow? Intervening early in children with bipolar disorder: is there a pot at the end of the Rainbow? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Intervening early in children with bipolar disorder: is there a pot at the end of the Rainbow? Article Text Expert commentary Intervening early in children with bipolar disorder: is there a pot

2015 Evidence-Based Mental Health

115. Substance Abuse in Canada: The Effects of Cannabis Use during Adolescence (Report)

Centre on Substance Abuse SUBSTANCE ABUSE IN CANADA—The Effects of Cannabis Use during Adolescence Cannabis remains the most commonly used illegal substance in Canada. Many people have used cannabis, or know someone who has, and infer from their first-hand knowledge that cannabis is a harmless or relatively benign substance that can be used safely. “I have tried marijuana several times and nothing bad has happened to me; it is less harmful than alcohol” is an oft-heard assertion. Although (...) functioning. • There is a link between cannabis and mental illness. • Some adverse effects might be irreversible, with the potential to seriously limit a young person’s educational, occupational and social development. Joy Johnson Vice-President, Research, Simon Fraser University References Bottorff, J.L., Johnson, J.L., Moffat, B.M., & Mulvogue, T . (2009). Relief-oriented use of marijuana by teens. Substance Abuse Treatment, Prevention, and Policy, 23(4), 7. Haines, R.J., Johnson, J.L., Carter, C.I

2015 Canadian Centre on Substance Abuse

116. Cannabis Regulation: Lessons Learned in Colorado and Washington State

banking operations, resulting in a primarily cash-based industry with corresponding safety and administrative issues. Although banking capacity has developed to an extent in Washington through smaller credit unions, transactions are limited to the production level and retail sales remain cash-based. The discrepancy also creates 1 The terms “cannabis” and “marijuana” both refer to the dried flowers, fruiting tops and leaves of Cannabis sativa. CCSA uses the term cannabis; this report uses the term (...) 1, 2014, by permitting existing licensed medical distributors to transfer to non-therapeutic sales. This approach leveraged Colorado’s existing framework for medical cannabis, which included state licensing. Retail licensing expanded to new retailers in October 2014. Licenses must be approved by both the Marijuana Enforcement Division of the Department of Revenue and relevant local licensing authorities, the latter of which have the authority to prohibit retail sales altogether. Of Colorado’s

2015 Canadian Centre on Substance Abuse

117. Use of Cannabis for Medicinal Purposes

, University of New South Wales. xv Department of Health Northern Territoty, Cannabis The Facts [Internet]. 2009. From: http://www.health.nt.gov.au/Alcohol_and_Other_Drugs/Cannabis/ Accessed 15 june 2015 xvi National Institute of Drug Abuse, What are Marijuana’s long term effects on the brain? [Internet]. 2015. From http://www.drugabuse.gov/about-nida/contact-us. Accessed 15 June 2015. xvii Meir M., Avshalom C., Ambler, A., Harrington. H., Houts. R., Keefe, R., et al. Persistent cannabis users show (...) Use of Cannabis for Medicinal Purposes POSITION PAPER ROYAL AUSTRALASIAN COLLEGE OF SURGEONS Subject: Use of Cannabis for Medicinal Purposes Ref. No. REL-GOV-034 Division: Relationships & Advocacy Document Owner: Director, Relationships & Advocacy Authorised By: Governance & Advocacy Committee Page 1 of 3 Original Issue: Version: Approval Date: Review Date: June 2015 1 June 2015 June 2018 INTRODUCTION Cannabis is the most commonly used illegal substance in Australia i and New Zealand ii

2015 Publication 80

118. Synthetic Cannabinoid Receptor Agonists: a heterogeneous class of novel psychoactive substance with emerging risk of psychosis

Synthetic Cannabinoid Receptor Agonists: a heterogeneous class of novel psychoactive substance with emerging risk of psychosis Synthetic Cannabinoid Receptor Agonists: a heterogeneous class of novel psychoactive substance with emerging risk of psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Synthetic Cannabinoid Receptor Agonists: a heterogeneous class of novel psychoactive substance with emerging risk of psychosis Article Text

2015 Evidence-Based Mental Health

119. Medical Marijuana For The Treatment Of Mental Illness

Cannabis Program. J Psychoactive Drugs. 2014 Jan;46(1):73-7. PubMed: PM24830188 PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: 1-866-898-8439 www.cadth.ca Medical Marijuana for Mental Illness 2 APPENDIX – FURTHER INFORMATION: Non-Randomized Study Conference Abstract 2. Reznik I. Medical cannabis use in post-traumatic stress disorder: a naturalistic observational study [Internet]. Abstract presented at: IACM 6thc conference on cannabinoids in medicine and 5th European workshop (...) on cannabinoid research; 2011; Sept. 8-10; Bonn (Germany). [cited 2014 Jul 30]. Available from: http://www.cannabis- med.org/studies/ww_en_db_study_show.php?s_id=481 Position Statement – Uncertain Methodology 3. Position statement on the use of medical marijuana for posttraumatic stress disorder [Internet]. Arlington (VA): American Psychiatric Association; 2013 Jul. [cited 2014 Jul 30]. Available from: http://www.google.ca/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=40&ved=0CFE QFjAJOB4&url=http%3A%2F

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

120. Medical Marijuana, Physicians, and State Law. Full Text available with Trip Pro

Medical Marijuana, Physicians, and State Law. 25099473 2014 09 16 2014 09 11 1533-4406 371 11 2014 Sep 11 The New England journal of medicine N. Engl. J. Med. Medical marijuana, physicians, and state law. 983-5 10.1056/NEJMp1408965 Annas George J GJ From the Department of Health Law, Bioethics, and Human Rights, Boston University School of Public Health, Boston. eng Journal Article 2014 08 06 United States N Engl J Med 0255562 0028-4793 0 Plant Preparations AIM IM Cannabis Ethics, Medical (...) Humans Legislation, Drug Marijuana Smoking legislation & jurisprudence Phytotherapy Plant Preparations therapeutic use State Government United States 2014 8 8 6 0 2014 8 8 6 0 2014 9 17 6 0 ppublish 25099473 10.1056/NEJMp1408965

2014 NEJM